The Myelodysplastic Syndromes (MDSs) are a heterogeneous group of myeloid malignancies characterized by clonal hematopoiesis, impaired differentiation, peripheral blood cytopenias, and increased risk of progression to acute myeloid leukemia. Although recent studies have identified recurrent somatic mutations in most patients with MDS, approximately 20% of patients with MDS had no known somatic